# Pembrolizumab in HNSCC With Residual Disease After Radiation

> **NCT02892201** · PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 9 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02892201
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09-08
- **Primary completion:** 2020-02
- **Final completion:** 2020-03
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02892201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02892201, "Pembrolizumab in HNSCC With Residual Disease After Radiation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02892201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*